Relationship between cryoglobulinemia-associated nephritis and HCV infection

References

• Roccatello D, Morsica G, Picciotto G et al. Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinemia and hepatitis C virus (HCV) infection. Clin. Exp. Immunol.110, 9–14 (1997).
   PubMedGoogle Scholar
• Colin W Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis.5, 558–567 (2005).
   Google Scholar
• Roccatello D, Fornasieri A, Giachino O et al. Multicenter study on HCV-related cryoglobulinemic glomerulonephritis. Am. J. Kidney Dis.49, 69–82 (2007).
   PubMed Web of Science ®Google Scholar
• Rustgi VK: The epidemiology of hepatitis C infection in the United States. J. Gastroenterol.42, 513–521 (2007).
   PubMed Web of Science ®Google Scholar
• Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr. Opin. Rheumatol.20, 23–28 (2008).
   PubMed Web of Science ®Google Scholar
• Ferri C, Pileri S, Zignego AL. Hepatitis C virus, B-cell disorders, and non-Hodgkin lymphoma. In: Infectious Cause of Cancer. Target for Intervention. Goedert JJ (Ed.). Humana Press, Totowa, NJ, USA 349–368 (2000).
   Google Scholar
• Fornasieri A, Li M, Armelloni S et al. Glomerulonephritis induced by human IgMκ–IgG cryoglobulins in mice. Lab. Invest.69, 531–540 (1993).
   Google Scholar
• Roccatello D, Isidoro C, Mazzucco G et al. Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int.43, 1150–1155 (1993).
   Google Scholar
• Misiani R, Mantero G, Bellavita P et al. GB virus C infection in patients with type II mixed cryoglobulinemia. Ann. Intern. Med.127, 891–894 (1997).
   Google Scholar
• Morsica G, Sitia G, Roccatello D. GB virus C and hepatitis C virus infection in patients with mixed cryoglobulinemia. Ann. Intern. Med.133, 394–395 (2000).
   Google Scholar
• Cacoub P, Rosenthal E, Gerolami V et al. Transfusion-associated TT virus co-infection in patients with hepatitis C virus is associated with type II mixed cryoglobulinemia but not with B-cell non-Hodgkin lymphoma. Clin. Microbiol. Infect.9, 39–44 (2003).
   PubMed Web of Science ®Google Scholar
• Rieu V, Cohen P, Andrè MH et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology41, 290–300 (2002).
   PubMed Web of Science ®Google Scholar
• Ferri C, Marzo E, Longombardo G et al. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood81, 1132–1136 (1993).
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D et al. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med.330, 751–756 (1994).
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D, Han JH et al. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood84, 3336–3343 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen P, Nguyen QT, Deny P et al. Treatment of mixed cryoglobulinemia with recombinant interferon-α and adjuvant therapies. A prospective study on 20 patients. Ann. Med. Interne147, 81–86 (1996).
   Google Scholar
• Casato M, Agnello V, Pucillo LP et al. Predictors of long term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood90, 3865–3873 (1997).
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Carniello GS, Colle R et al. Interferon therapy in HCV-positive mixed cryoglobulinemia: viral and host factors contributing to efficacy of therapy. Ital. J. Gastroenterol. Hepatol.29, 343–350 (1997).
   Google Scholar
• Calleja JL, Albillos A, Moreno-Otero R et al. Sustained response to interferon-α or to interferon-α plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment. Pharmacol. Ther.13, 1179–1186 (1999).
   Google Scholar
• Zuckerman E, Keren D, Slobodin G et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J. Rheumatol.27, 2172–2178 (2000).
   PubMed Web of Science ®Google Scholar
• Donada C, Crucitti A, Donadon V, Chemello L, Alberti A. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood92, 2983–2984 (1998).
   Google Scholar
• Mazzaro C, Zorat F, Comar C et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J. Rheumatol.30, 1775–1781 (2003).
   PubMed Web of Science ®Google Scholar
• Rossi P, Bertani T, Baio P et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int.63, 2236–2241 (2003).
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med.347, 89–94 (2002).
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia18, 1711–1716 (2004).
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J. Clin. Oncol.23, 468–473 (2005).
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood105, 74–76 (2005).
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Zorat F, Caizzi M et al. Treatment with peg-interferon α-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J. Hepatol.42, 632–638 (2005).
   PubMed Web of Science ®Google Scholar
• Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon α-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum.52, 911–915 (2005).
   PubMed Web of Science ®Google Scholar
• Hauser SC, Pardi DS, Poterucha JJ. Mayo Clinic Gastroenterology and Hepatology Board Review. Mayo Clinic Scientific Press, MN, USA 279 (2006).
   Google Scholar
• Liang TJ. Shortened therapy for hepatitis C virus genotype 2 or 3. Is less more? N. Engl. J. Med.357, 176–178 (2007).
   Google Scholar
• Ali S, Meidinger RR, Kayali Z et al. Outcomes of pegylated interferon and ribavirin therapy for HCV patients with cryoglobulinemia as compared to patients without cryoglobulinemia. Gastroenterology132, A790 (2007).
   Google Scholar
• Tarantino A, Campise M, Banfi G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int.47, 618–623 (1995).
   PubMed Web of Science ®Google Scholar
• Ma S, Boerner JE, TiongYip C et al. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents Chemother.50, 2976–2982 (2006).
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood101, 3818–3826 (2003).
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood101, 3827–3834 (2003).
   PubMed Web of Science ®Google Scholar
• Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol. Dial. Transplant.19, 3054–3061 (2004).
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology45, 842–846 (2006).
   PubMed Web of Science ®Google Scholar
• Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal-transplant patients. Transplantation80, 1560–1564 (2005).
   PubMed Web of Science ®Google Scholar
• Visentini M, Granata M, Veneziano ML et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin. Immunol.125, 30–33 (2007).
   PubMed Web of Science ®Google Scholar